Fabhalta

Novartis' Complement Inhibitor Fabhalta Approved for IgAN
Contract Pharma
Mon, 08/12/24 - 05:52 pm
FDA
Novartis
Fabhalta
primary IgA nephropathy
FDA approves Novartis' kidney disease drug
Reuters
Wed, 08/7/24 - 11:02 pm
Novartis
FDA
Fabhalta
kidney disease
paroxysmal nocturnal hemoglobinuria
Novartis Eyes Rare Kidney Disease Approvals on Heels of Two Phase III Wins
BioSpace
Tue, 05/28/24 - 10:47 am
Novartis
kidney disease
atrasentan
IgA nephropathy
Fabhalta
Novartis touts surrogate endpoint win, nabs priority review for Fabhalta in IgAN
Fierce Pharma
Mon, 04/15/24 - 09:32 pm
Novartis
Fabhalta
IgAN
priority review
FDA
Novartis unveils promising Fabhalta data for C3 glomerulopathy indication
Medical Marketing and Media
Tue, 12/12/23 - 09:56 am
Novartis
clinical trials
Fabhalta
iptacopan
C3 glomerulopathy
Novartis receives FDA approval for Fabhalta to treat PNH in adults
Pharmaceutical Business Review
Wed, 12/6/23 - 10:25 am
Novartis
FDA
Fabhalta
iptacopan
PNH
paroxysmal nocturnal hemoglobinuria